278 related articles for article (PubMed ID: 37156483)
1. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ; Wilson NR; Pemmaraju N
Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
[TBL] [Abstract][Full Text] [Related]
3. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
4. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
5. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
8. Tagraxofusp in myeloid malignancies.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
[TBL] [Abstract][Full Text] [Related]
9. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
Cheng W; Yu TT; Tang AP; He Young K; Yu L
Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
[TBL] [Abstract][Full Text] [Related]
10. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wilson NR; Pemmaraju N
Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
12. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
[No Abstract] [Full Text] [Related]
14. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of 46 cases with CD4
Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
[TBL] [Abstract][Full Text] [Related]
16. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
17. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
18. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
Cangini D; Silimbani P; Cafaro A; Giannini MB; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
20. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]